Although specific molecular mechanisms of how TRAF3 or CYLD loss leading to constitutive activation of NF-κB sensitizes HPV+ HNSCC to radiation are still being investigated, our findings suggest that therapeutic NF-κB activation may increase radiation response in the subtype of these tumors harboring low NF-κB activity. This evidence concerns the gene CYLD and head and neck squamous cell carcinoma.